Firms

DCVC

San Jose, California · San Francisco, California · Cambridge, Massachusetts · Palo Alto, California · San Francisco Bay Area

dcvc.com

signal.nfx.com

goldi.ai

DCVC backs entrepreneurs using Deep Tech to solve problems and multiply the benefits of capitalism for everyone while reducing its cost. Deep Tech is a potent approach to this challenge that enables more for less - now and for this century. The transformative companies in their portfolio combine the latest advances in science and technology withunique compute and algorithmic advantage, reducing CAPEX and OPEX.

Founded: 2011
Type: Venture capital

Funds4

DCVC VII2026-05-222026-05-22—
FormD/A signed2026-05-22: USD800M total offering, USD602512625 sold, USD197487375 remaining. Firstsale2025-05-01. Sold partner commitments, not finalclose; amount field omitted.
DCVC Bio III2024-09-302024-09-30$400M
DCVC Bio separate strategy: USD400M closed, USD350M originaltarget. CNS/neuroimmune therapeutics not direct neuraldevices.
DCVC Climate I2024-09-302024-09-30—
First dedicated Climate fund closed alongside BioIII for over USD700M combined; standalone amount undisclosed, aggregate not assigned here.
DCVC Bio II2020-08-052020-08-05$350M
Second life-sciences fund closed at USD350m, investing in therapeutics, agriculture and industrial biotechnology.

Team

Investments

team@apexlogos.ai13 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities. Fund size and status | Vehicle / measure | Amount and status | Dated evidence / caveat | |---|---|---| | DCVC VII, L.P., incorporated 2025 | **US$800,000,000 total offering; US$602,512,625 sold; US$197,487,375 remaining** | SEC Form D/A signed **2026-05-22**; first sale **2025-05-01**. Sold includes commitments of all partners. This is a fundraising filing, not evidence of a final US$800m close. [SEC filing](https://www.sec.gov/Archives/edgar/data/2052581/000205258126000002/xslFormDX01/primary_doc.xml). | | Seventh flagship plus second energy/climate fund | **US$1.3bn combined target**, reported June 2026 | Axios preview dated **2026-06-16** reports aggregate fundraising plans. Full reporting was paywalled; allocation and final closing status were not verified. [Axios](https://www.axios.com/pro/climate-deals/2026/06/16/dcvc-fervo-boost). | | DCVC Bio III | **US$400m closed**, originally targeted US$350m | Official **2024-09-30** announcement says oversubscribed third main Bio fund. [Bio III close](https://www.dcvc.com/news-insights/dcvc-bio-iii-closes-at-400-million/). | | First dedicated DCVC Climate fund + DCVC Bio III | **Over US$700m closed collectively** | Official **2024-09-30** announcement. This total includes Bio III; do not add both as distinct capital pools. Exact standalone Climate amount is not specified in this announcement. [Combined close](https://www.dcvc.com/news-insights/dcvc-closes-700-million-in-new-funds/). | | Fresh capital announced in 2023 | **More than US$1bn**, aggregate | Official **2023-07-21** announcement does not provide the complete fund-by-fund breakdown in the text checked. [Announcement](https://www.dcvc.com/news-insights/dcvc-announces-1-billion-in-fresh-funding-releases-inaugural-dcvc-deep-tech-opportunities-report/). | | Historical committed capital | **More than US$3bn across 12 funds** | 2023 official report; historical committed capital, not a current AUM estimate or one fund. [2023 report](https://www.dcvc.com/uploads/Reports/DTOR-23/DCVC-2023-Deep-Tech-Opportunities-Report.pdf). | Searches for newer 2025–2026 funds identified VII and the combined 2026 target. Latest-known public status is provided; no final VII or second Climate close was verified. The 2024 statement that over US$1.6bn closed in the preceding two-and-a-half years is another overlapping aggregate, not additive to the table's constituent funds. Additional fund evidence checked in the final pass: - DCVC Bio II: [source](https://www.dcvc.com/news-insights/life-sciences-and-deep-tech-the-next-set-of-solutions-to-the-next-set-of-problems/). Funds recorded in Adex after this review: | Fund | Disclosed amount | Announcement / filing date | | --- | --- | --- | | DCVC Bio II | USD 350000000 | 2020-08-05 | | DCVC Bio III | USD 400000000 | 2024-09-30 | | DCVC Climate I | Undisclosed / unverified | 2024-09-30 | | DCVC VII | Undisclosed / unverified | 2026-05-22 |
team@apexlogos.ai14 hours ago
Match research 2026-10-06 / DCVC / sha256:b9a622ffd145a8eca58f13e27aa84388727f7b72caeacd3083dd727ce87c7010 / part 2 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. - **Latus Bio:** DCVC Bio co-led the 2024-05-02 US$54m initial Series A. CNS-targeted gene therapy includes Huntington's disease and CLN2 disease. The AAV delivery engineering is technologically substantive, but classification here is **CNS gene therapy / neurobiology adjacent to device neurotech**. The investee's news page also lists a 2026 financing item; this brief verifies the prior 2024 round, not participation in every later round. [Launch release](https://www.dcvc.com/press-releases/latus-launches-with-state-of-the-art-gene-therapy-development-technologies-two-lead-product-candidates-and-an-initial-54-million-in-series-a-financing/) (2024-05-02); [Latus news](https://www.latusbio.com/news-publications) (accessed 2026-10-06). - **Nilo Therapeutics:** DCVC Bio III's official 2024-09-30 announcement names Nilo as an investment. Its technology studies brain neural circuits controlling inflammation to discover medicines for immune diseases. Official portfolio gives first investment **2024**. This is **neuroimmune drug discovery**, not an implanted interface. A saved Adex financing lead says US$101m Series A in October 2025; that later financing amount was not independently finalized here. [Bio III announcement](https://www.dcvc.com/news-insights/dcvc-bio-iii-closes-at-400-million/) (2024-09-30); [Nilo portfolio](https://www.dcvc.com/companies/nilo-therapeutics/) (accessed 2026-10-06). - **Newleos Therapeutics:** Official portfolio says first investment **2025**. The firm's 2025 report explicitly says DCVC Bio participated in the February 2025 Series A and describes licensed neuropsychiatric drug candidates, including GABA signaling for anxiety. This is **neuropsychiatric therapeutics**, not neural hardware. The saved Adex US$93.5m round amount is consistent with reporting, but do not treat this as the firm's check. [Official portfolio](https://www.dcvc.com/companies/newleos-therapeutics/) (accessed 2026-10-06); [2025 official report](https://www.dcvc.com/uploads/Reports/DTOR-25/DCVC-2025-Deep-Tech-Opportunities-Report.pdf) (2025). - **Avicenna Biosciences:** Official portfolio identifies first investment **2022** and a machine-learning medicinal chemistry platform whose neurodegeneration program includes ROCK inhibition. Bio III's announcement identifies Parkinson's/ALS applications. This is **AI-enabled CNS drug discovery**. No specific initial round amount is asserted here. [Portfolio](https://www.dcvc.com/companies/avicenna-biosciences/) (accessed 2026-10-06); [Bio announcement](https://www.dcvc.com/news-insights/dcvc-bio-iii-closes-at-400-million/) (2024-09-30). The saved **Nervana Systems** entries should not be categorized as neurotech solely from the name: AI compute is distinct from measuring or modulating the nervous system. Similarly, DCVC's publications discussing BCI opportunities do not prove investment in the companies mentioned. Searches pairing DCVC with Cala, Neuralink, Synchron and Paradromics did not establish firm investment attribution. ## Conflicts, gaps and concrete review notes 1. Review founding **2011 in Adex vs 2010 official**; keep the discrepancy explicit until resolved. 2. Preserve vehicle attribution: DCVC Bio III is distinct from the flagship VII and Climate vehicles. Keep US$700m+ multi-fund close, US$400m Bio close and US$800m VII offering separate; retain the dated US$602.5m VII sold amount without calling it final close. 3. Current check-size policy and standalone first/second Climate closing amounts remain unverified. Do not substitute NFX person ranges or total investment-round sizes. 4. Audit saved participations sourced solely to generic Goldi pages. Adex's Recursion US$239m entry links to a `series-d` URL while marking stage `series-a`; correct only after source-level verification. Multiple Mainspring, Solu, Brimstone and other company aliases can inflate apparent deal counts. 5. Neurobiology companies provide credible scientific exposure, but do not justify a direct neurodevice track-record claim. Named examples above retain the Bio affiliation and distinguish therapeutic mechanisms from interfaces. 6. This brief verifies representative relevant investments, not every historical snapshot row or current ownership/exit status. Portfolio pages are investor-authored evidence; financing releases are issuer statements. The June 2026 Axios full article was not accessible. No source established an exhaustive current list of funds or neurotech investments.
team@apexlogos.ai14 hours ago
Match research 2026-10-06 / DCVC / sha256:b9a622ffd145a8eca58f13e27aa84388727f7b72caeacd3083dd727ce87c7010 / part 1 of 2 Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats. # DCVC (Data Collective) - **Exact Adex ID:** `DCVC` - **Canonical Adex URL:** https://adex.page/firms/DCVC - **Research date / access date:** 2026-10-06 - **Status:** Complete research brief for later Adex review; no database changes. DCVC is a US deep-tech venture investor with flagship, climate and separately identified DCVC Bio strategies. Verified examples span enhanced geothermal, advanced filtration materials, computational drug discovery and engineered CNS gene delivery. Its official strategy supports early-stage through growth investing. Brain-related biotechnology investments are verified, but a direct BCI, neural recording or neuromodulation device investment was not verified in this review. Fund amounts below distinguish closed commitments, offering targets and multi-fund totals. ## Starting evidence and identity The saved read-only Adex snapshot `_sources/DCVC.adex.json` (retrieved 2026-10-06) contains the exact `DCVC` firm record, the Match label, a description emphasizing science plus computation, founded year 2011, and null minimum/maximum/sweet-spot check fields. Its historical investment entries include Fervo, ZwitterCo, Latus-related biology leads, Newleos, Nilo, Nervana, Recursion, Quantum Motion, robotics and many others. Some claims cite broad Goldi co-investor pages rather than investee announcements, and some entries appear duplicated under company-name variants. This is starting evidence, not verification of all saved participation claims. Official DCVC pages describe the firm as active since **2010**, conflicting with Adex's 2011 founding year. DCVC Bio was established in **2018** and uses its own funds; a DCVC Bio investment should retain that attribution rather than silently becoming a flagship investment. [Official homepage](https://www.dcvc.com/), [official Bio strategy](https://www.dcvc.com/bio/) (undated, accessed 2026-10-06). **NFX Signal:** https://signal.nfx.com/firms/data-collective. The initial direct browser retrieval exposed firm/team content; repeated retrievals yielded a thin page shell, so specific numerical claims were recovered from the search-indexed version. Signal associates John Blumenthal, Zachary Bogue and Chris Boshuizen with US$5m–25m ranges and US$15m sweet spots, with seed, Series A and Series B deep-tech/space/climate categories. These are person-profile directory claims, not a verified uniform current firm check policy. Signal intro paths require sign-in. Do not fill Adex check-size fields from these numbers without firm confirmation. [Signal firm page](https://signal.nfx.com/firms/data-collective) (undated, accessed 2026-10-06). ## Fund size and status | Vehicle / measure | Amount and status | Dated evidence / caveat | |---|---|---| | DCVC VII, L.P., incorporated 2025 | **US$800,000,000 total offering; US$602,512,625 sold; US$197,487,375 remaining** | SEC Form D/A signed **2026-05-22**; first sale **2025-05-01**. Sold includes commitments of all partners. This is a fundraising filing, not evidence of a final US$800m close. [SEC filing](https://www.sec.gov/Archives/edgar/data/2052581/000205258126000002/xslFormDX01/primary_doc.xml). | | Seventh flagship plus second energy/climate fund | **US$1.3bn combined target**, reported June 2026 | Axios preview dated **2026-06-16** reports aggregate fundraising plans. Full reporting was paywalled; allocation and final closing status were not verified. [Axios](https://www.axios.com/pro/climate-deals/2026/06/16/dcvc-fervo-boost). | | DCVC Bio III | **US$400m closed**, originally targeted US$350m | Official **2024-09-30** announcement says oversubscribed third main Bio fund. [Bio III close](https://www.dcvc.com/news-insights/dcvc-bio-iii-closes-at-400-million/). | | First dedicated DCVC Climate fund + DCVC Bio III | **Over US$700m closed collectively** | Official **2024-09-30** announcement. This total includes Bio III; do not add both as distinct capital pools. Exact standalone Climate amount is not specified in this announcement. [Combined close](https://www.dcvc.com/news-insights/dcvc-closes-700-million-in-new-funds/). | | Fresh capital announced in 2023 | **More than US$1bn**, aggregate | Official **2023-07-21** announcement does not provide the complete fund-by-fund breakdown in the text checked. [Announcement](https://www.dcvc.com/news-insights/dcvc-announces-1-billion-in-fresh-funding-releases-inaugural-dcvc-deep-tech-opportunities-report/). | | Historical committed capital | **More than US$3bn across 12 funds** | 2023 official report; historical committed capital, not a current AUM estimate or one fund. [2023 report](https://www.dcvc.com/uploads/Reports/DTOR-23/DCVC-2023-Deep-Tech-Opportunities-Report.pdf). | Searches for newer 2025–2026 funds identified VII and the combined 2026 target. Latest-known public status is provided; no final VII or second Climate close was verified. The 2024 statement that over US$1.6bn closed in the preceding two-and-a-half years is another overlapping aggregate, not additive to the table's constituent funds. ## Investment stages The official 2023 report explicitly describes investing from **early-stage startups to established growth businesses**. Historical transactions independently support seed (Relation), Series A (ZwitterCo; Latus through Bio), and later-stage participation (Fervo Series E). This demonstrates breadth; it does not establish that every fund uses an identical mandate. DCVC Bio describes backing scientific platforms and teams before conventional clinical-stage biotech milestones. [2023 strategy report](https://www.dcvc.com/uploads/Reports/DTOR-23/DCVC-2023-Deep-Tech-Opportunities-Report.pdf) (2023); [Bio III strategy](https://www.dcvc.com/news-insights/dcvc-bio-iii-closes-at-400-million/) (2024-09-30). ## Named verified deep-tech investments Round amounts are company financing totals, **not DCVC's individual checks**. | Company | Technology rationale | Firm attribution and dated financing | Sources | |---|---|---|---| | **Fervo Energy** | Enhanced geothermal combines horizontal drilling and fiber-optic sensing to develop otherwise difficult geothermal reservoirs. | DCVC states it led Series C in 2022 and supported the **US$462m Series E announced 2025-12-10**. Series E lead was B Capital, not DCVC. | [DCVC detailed announcement](https://www.dcvc.com/news-insights/fervo-raises-462m-to-power-the-grids-zero-carbon-future/) (2025-12-10). | | **ZwitterCo** | Zwitterionic copolymer membranes resist fouling in industrial wastewater, a materials/chemical-engineering innovation. | DCVC explicitly **led US$33m Series A**, announced **2022-09-15**; official portfolio says first investment 2021. | [DCVC financing/technology account](https://www.dcvc.com/news-insights/an-increasingly-dry-world-will-demand-water-reuse/) (2022-09-15); [portfolio](https://www.dcvc.com/companies/zwitterco/) (undated, accessed 2026-10-06). | | **Relation Therapeutics** | Machine learning and experimental biological datasets to identify causal disease mechanisms and drug targets; computational biology rather than ordinary SaaS. | **US$35m new seed financing**, **2024-03-14**, led by DCVC with NVentures as co-lead. | [Company release hosted by DCVC](https://www.dcvc.com/press-releases/relation-therapeutics-secures-35-million-of-new-seed-financing-led-by-dcvc-and-co-lead-nventures-nvidias-venture-arm/) (2024-03-14). | | **Latus Bio** | Engineered AAV capsids and screening technologies for precise CNS gene delivery. | **DCVC Bio**, with 8VC, co-led initial **US$54m Series A close, 2024-05-02**. First investment 2024. | [Launch release](https://www.dcvc.com/press-releases/latus-launches-with-state-of-the-art-gene-therapy-development-technologies-two-lead-product-candidates-and-an-initial-54-million-in-series-a-financing/) (2024-05-02); [official portfolio](https://www.dcvc.com/companies/latus-bio/) (accessed 2026-10-06). | ## Neurotech and neuroscience distinctions **No verified neurotech investment found in the sources checked** when neurotech means direct neural sensing, BCI or neural stimulation devices. This is a bounded research result, not a claim that DCVC has never invested in the sector. Verified brain-related investments are primarily therapeutic biotechnology:
team@apexlogos.ai23 days ago
MATCH

Jason Pontin DCVC, general_partner	$15M$5M – $25M	Palo Alto, California · Cambridge, Massachusetts
Alan Cohen DCVC, general_partner	$15M$5M – $25M	San Francisco Bay Area
Ali Tamaseb DCVC, general_partner	$15M$5M – $25M	San Francisco Bay Area
Armen Vidian DCVC, partner	$15M$5M – $25M	San Francisco, California
Chris Boshuizen DCVC, partner	$15M$5M – $25M	San Francisco, California
Michael Driscoll DCVC, partner	$15M$5M – $25M	San Francisco, California
Rachel Slaybaugh DCVC, general_partner	$15M$5M – $25M	San Francisco, California
Todd Papaioannou DCVC, partner	$15M$5M – $25M	San Jose, California
Milo Werner DCVC, general_partner	$3M$250K – $9M	Cambridge, Massachusetts
Matt Ocko DCVC, managing_partner	$1M$100K – $25M	Palo Alto, California
Spencer Punter DCVC, partner	$1M$250K – $3M	San Francisco Bay Area
Kelly Chen DCVC, partner	$1M$250K – $3M	San Francisco, California
Scott Barclay DCVC, partner	—$10M – $350M	Palo Alto, California
Stephen Seymour DCVC, associate	—$5M – $25M	Palo Alto, California
Irfan Ahmad DCVC, partner	—$5M – $25M	San Francisco Bay Area
James Hardiman DCVC, partner	—$5M – $25M	San Francisco Bay Area
Jeremy Joseph DCVC, investor	—$5M – $25M	San Francisco, California
John Blumenthal DCVC, partner	—$5M – $25M	San Francisco, California
Luca Parolari DCVC, senior_associate	—$5M – $25M	San Francisco, California
Zachary Bogue DCVC, managing_partner	—$5M – $25M	San Francisco, California
Aimee Villamayor DCVC, Office Manager & Executive Assistant, DCVC Bio	—— – —
Allyson Kaufman DCVC, Investor Relations Partner	—— – —
Cara Yesko DCVC, Associate	—— – —
Carly Smith DCVC, Office Assistant, DCVC Bio	—— – —
Christopher Meldrum DCVC, Entrepreneur In Residence, DCVC Bio	—— – —
Clara Chang, CPA DCVC, VP, Finance	—— – —
Clay Hutmacher DCVC, Operating Partner	—— – —
Darletha Morgan DCVC, Office Assistant	—— – —
Dr. Adil Anjem DCVC, Entrepreneur In Residence, DCVC Bio	—— – —
Dr. Andy May DCVC, Operating Partner, DCVC Bio	—— – —
Dr. Emily Park DCVC, Principal, DCVC Bio	—— – —
Dr. John Hamer DCVC, Managing Partner, DCVC Bio	—— – —
Dr. Josué López DCVC, Principal	—— – —
Dr. Justin Kern DCVC, Partner, DCVC Bio	—— – —
Dr. Kiersten Stead DCVC, Managing Partner, DCVC Bio	—— – —
Dr. Linda Maxwell DCVC, Operating Partner	—— – —
Dr. Prineha Narang DCVC, Operating Partner	—— – —
Dr. Rachel Slaybaugh DCVC, General Partner	—— – —
Dr. Stephen Beaton DCVC, Entrepreneur In Residence	—— – —
Dr. Vandon Duong DCVC, Principal	—— – —
Earl Jones DCVC, Operating Partner	—— – —
Emily Deng DCVC, Principal, Investor Relations	—— – —
Fiona Liu, CPA DCVC, Assistant Controller	—— – —
Flo Thinh Chialtas DCVC, Talent Partner	—— – —
Gregg Rotenberg DCVC, Operating Partner	—— – —
Hailey Hiss DCVC, Director, Communications	—— – —
Jack Sauls DCVC, Associate	—— – —
Josh Pickering DCVC, Chief of Staff	—— – —
Kristen Rocca DCVC, Principal	—— – —
Linda Chang DCVC, Director, Finance	—— – —
Luis Bacalao DCVC, Chief Legal Officer and General Counsel	—— – —
Matt O'Connell DCVC, Operating Partner	—— – —
Matthew Ocko DCVC, Co-Founder and Managing Partner	—— – —
Nate Nickerson DCVC, Communications and Public Affairs Partner	—— – —
Olivia Souder DCVC, Director, Operations	—— – —
Rebecca Gedeon DCVC, Executive Assistant	—— – —
Richard Waines DCVC, Senior Associate, DCVC Bio	—— – —
Season Flores DCVC, Executive Assistant	—— – —
Serge Messerlian DCVC, Operating Partner, DCVC Bio	—— – —
Stephen Rodriguez DCVC, Operating Partner	—— – —
Steve Crossan DCVC, Operating Partner	—— – —

$25M2026-07-09	Alchemab Therapeutics	DCVC
€411M2026-07-07	Proxima Fusion	Lightspeed, DCVC, Burda Principal Investments, Plural Platform, UVC Partners, SPRIND, Balderton Capital, Cherry Ventures, Elaia, Plural, Redalpine
$160M2026-05-07	Quantum Motion Technologies	Bosch Ventures, DCVC
$220M2026-03-25	Halter	Founders Fund, BOND, Blackbird, DCVC, Ubiquity Ventures, NewView Capital, Bessemer Venture Partners
$10M2026-03-13	AgZen	DCVC
$34M2026-02-25	Chariot Defense	General Catalyst, DCVC, Marlinspike, Arches Capital, Overmatch Ventures, Ensemble VC, Paul Kwan
$102M2026-02-04	Lunar Energy	DCVC
$—2026-01-09	Mitosis	DCVC
$125M2025-12-17	Mythic	DCVC, Future Ventures, Rouz Jazayeri, Matt Ocko
$26M2025-12-09	Relation Therapeutics	DCVC, Jason Pontin
$—2025-12-09	Unconventional AI	Lightspeed, DCVC, Lux Capital
$30M2025-11-17	Electronx	DCVC, Innovation Endeavors, SYSTEMIQ Capital
$60M2025-10-20	Seneca	DCVC, First Round
$101M2025-10-08	NILO Therapeutics	DCVC, Lux Capital
$70M2025-08-06	Chai Discovery	Menlo Ventures, DCVC
$165M2025-06-24	Halter	Founders Fund, BOND, Blackbird, DCVC, Ubiquity Ventures, NewView Capital, Bessemer Venture Partners
$30M2025-06-20	Insight M	DCVC, Zachary Bogue
€130M2025-06-11	Proxima	Balderton Capital, Cherry Ventures, DCVC, Plural
$50M2025-06-10	AIM	Khosla Ventures, General Catalyst, Human Capital, Mantis Venture Capital, DCVC, Ironspring Ventures, Elad Gil, Sven Strohband
$10M2025-05-08	Alta Resource Technologies	DCVC
$30M2025-04-23	Grove Biopharma	DCVC
$258M2025-04-14	Mainspring Energy	General Catalyst, Temasek Holdings (Private) Limited, DCVC, Lightrock, Khosla Ventures, Gates Frontier, Marunouchi Innovation Partners
$258M2025-04-14	Mainspring	General Catalyst, Temasek Holdings (Private) Limited, DCVC, Lightrock, Khosla Ventures, Gates Frontier, Marunouchi Innovation Partners
$41M2025-04-09	Solu	DCVC
$10M2025-03-06	AgZen	DCVC
$100M2025-01-14	Umoja	Double Point Ventures, DCVC
$2M2025	OraLiva	DCVC
$11M2025	Estes	DCVC
$28M2024-12-17	Slip Robotics	DCVC, James Hardiman
$100M2024-11-14	Radiant Industries	DCVC, Andreessen Horowitz, Union Square Ventures, Felicis, Washington Harbour Partners, Chevron Technology Ventures, Founders Fund, Decisive Point, McKinley Alaska, Boost VC, Also Capital
$—2024-10-25	Agility Robotics	DCVC
$53M2024-10-24	Fable Therapeutics	DCVC
$33M2024-10-22	Reality Defender	Y Combinator, DCVC, IBM Ventures, Partnership Fund for New York City, Illuminate Financial, Booz Allen Hamilton, Ali Tamaseb
$130M2024-10-09	Zap Energy	DCVC
$150M2024-10-01	Impulse Space	Founders Fund, Airbus Ventures, Alumni Ventures, DCVC, 137 Ventures, Balerion Space Ventures, Lux Capital, Jackson Moses
$200M2024-09-19	Twelve	DCVC, Zachary Bogue
$8M2024-09-19	Tidal Metals	DCVC
$32M2024-07-29	unspun	DCVC, Milo Werner
$12M2024-07-01	Kanvas Biosciences	DCVC
$35M2024-03-14	Relation	DCVC, Khosla Ventures, NVentures, Deerfield, Magnetic
$—2024-02-27	Fervo Energy	DCVC
$254M2024-02-15	Freenome	Bain Capital, DCVC, Roche Venture Fund, Cormorant Asset Management, Pura Vida Investments, Andreessen Horowitz (a16z) Bio + Health
$52M2024-01-03	Radionetics Oncology	DCVC
$7M2024	Delphos Labs	DCVC, Decibel
$66M2023-12-15	Totus Medicines	DCVC, Afore Capital, Jason Pontin
$15M2023-10-17	Reality Defender	DCVC, Ali Tamaseb
$79M2023-10-04	Mach Industries	DCVC
$29M2023-08-29	CH4 Global	DCVC, Zachary Bogue
$81M2023-05-16	Auradine	Celesta Capital, DCVC
$132M2023-03-20	Ascend Advanced Therapies	DCVC
$13M2023-03-09	Mythic	DCVC, Lux Capital, Catapult Ventures, Hermann Hauser, Rouz Jazayeri, Shahin Farshchi, Matt Ocko
$135M2023-03-01	Chroma Medicine	ARCH Venture Partners, Casdin Capital, Atlas Venture, DCVC, Wellington Management, Cormorant Asset Management, Osage University Partners
$17M2023-02-23	Aquafortus	DCVC, Matt Ocko, Jason Pontin
$17M2023-02-21	Fortem	DCVC
$20M2023-02-15	Elo Life	DCVC
$17M2023-02-06	Recycleye	DCVC
$8M2023-01-10	Nest Genomics	Y Combinator, Casdin Capital, DCVC, Samsung Next, B Capital, LionBird
$125M2023	Mythic AI	DCVC
$24M2022-11-03	Smartex	Lightspeed, Build Collective, DCVC, HAX, Momenta, H&M Group Ventures
$—2022-11-01	Samsara Eco	DCVC
$33M2022-09-15	ZwitterCo	DCVC, Genoa Ventures, Jason Pontin
$35M2022-09-12	lumafield	DCVC, Lux Capital
$17M2022-08-18	Sabanto Ag	DCVC
$17M2022-08-18	Sabanto	DCVC
$12M2022-08-04	Rill Data	DCVC, Sierra Ventures, Anthony Goldbloom, Florian Leibert
$48M2022-07-20	Auron Therapeutics	DCVC
$150M2022-04-22	Agility Robotics	DCVC, Playground Global
$50M2022-04-19	Unlearn.AI	8VC, DCVC, Radical Ventures
$—2022-04-08	Aclarity	DCVC
$5M2022-03-29	zkLend	DCVC, Ali Tamaseb
$18M2022-03-21	Plotlogic	Innovation Endeavors, DCVC, Samantha Smith-Eppsteiner
$40M2022-03-08	Creyon Bio	DCVC, Lux Capital
$102M2022-02-23	Plexium	CRV, DCVC, Lux Capital
$60M2022-01-20	Atom Computing, Inc.	DCVC, Innovation Endeavors
$125M2022-01-13	MycoWorks	Prime Movers Lab, DCVC
$20M2022	Avicenna Biosciences	DCVC
$50M2022	Unlearn	8VC, DCVC, Radical Ventures
$—2021-12-09	Totus Medicines	DCVC
$300M2021-12-07	Freenome	Vasudev Bailey, Bain Capital, Catalio Capital Management, DCVC, Roche Venture Fund, S32, Pura Vida Investments, Cowen Healthcare Investments, Section 32
$25M2021-11-30	Q Ctrl	DCVC, Sierra Ventures, James Hardiman, Ben Yu
$25M2021-11-19	Kettle	DCVC
$27M2021-11-18	Gradle Inc.	Bain Capital, DCVC, StepStone Group, True Ventures, Harmony Partners, Triangle Peak Partners, James Hardiman
$54M2021-10-21	Jupiter	DCVC, SYSTEMIQ Capital
$2M2021-10-18	Trustpoint	DCVC, Chris Boshuizen
$40M2021-10-07	Kentik	DCVC
$64M2021-10	MosaicML	DCVC, Frontline Ventures, Lux Capital, Playground Global
$19M2021-09-16	SafelyYou	Founders Fund, Foundation Capital, Anorak Ventures, The House Fund, Swift Ventures, DCVC
$19M2021-09-16	Safelyyou	Founders Fund, Foundation Capital, Anorak Ventures, The House Fund, Swift Ventures, DCVC, Eclipse
$19M2021-09-16	SafelyYou	Founders Fund, Foundation Capital, Anorak Ventures, The House Fund, Swift Ventures, DCVC
$19M2021-09-16	SafelyYou	Founders Fund, Foundation Capital, Anorak Ventures, The House Fund, Swift Ventures, DCVC
$5M2021-08-24	MindRhythm	DCVC, Pierre Lamond
$—2021-07-20	Pivot Bio	DCVC
$210M2021-06-21	Umoja	DCVC
$60M2021-04-15	Alchemab Therapeutics	DCVC
$—2021-03-09	BioPhero	DCVC
$35M2021-01-21	Plexium	Lux Capital, DCVC
$—2021-01-01	Pivot Bio	DCVC
$125M2021-01-01	MycoWorks	DCVC
$2M2021	Trustpoint	DCVC
$35M2021	Swift Medical	DCVC
$12M2020-11-19	Subtle Medical	DCVC
$53M2020-11-18	Umoja	DCVC
$45M2020-11-17	MycoWorks	8VC, DCVC
$100M2020-11-10	Carbon Health	DCVC
$14M2020-09-30	Golden	DCVC
$239M2020-09-09	Recursion Pharmaceuticals	DCVC, Felicis, Lux Capital, Laurion Capital Management
$79M2020-08-04	Rigetti	Bessemer Venture Partners, DCVC
$53M2020-07-20	Caption	Khosla Ventures, Atlantic Bridge, DCVC, Data Collective, Founders Future
$53M2020-07-15	Caption Health	Khosla Ventures, Atlantic Bridge, DCVC, Armen Vidian
$3M2020-06-22	Horizon Quantum	DCVC
$23M2020-06-17	Proprio	DCVC, Alan Cohen, Armen Vidian
$23M2020-05-27	Kentik	DCVC
$—2020-05-27	AbCellera	Founders Fund, OrbiMed, University of Minnesota, DCVC, Viking Global Investors, Presight Capital
$—2020-04-24	Biobot Analytics	Y Combinator, DCVC, Engine Ventures
$165M2020-02-24	Karius	General Catalyst, Innovation Endeavors, Tencent Investment, DCVC, Khosla Ventures, Lightspeed
$18M2020-01-28	Advano	Y Combinator, Build Collective, Thiel Capital, DCVC, Thrive Capital, PeopleFund
$30M2020-01-08	Evolv Technology	General Catalyst, DCVC, Lux Capital, SineWave Ventures
$—2020-01-08	Evolv Technologies	General Catalyst, DCVC, Lux Capital, Osage University Partners, SineWave Ventures
$79M2020	Rigetti	Y Combinator, Alumni Ventures, Franklin Templeton, DCVC, EDBI, Morpheus Ventures, Bessemer Venture Partners
$17M2019-12-31	MycoWorks	DCVC, 8VC
$11M2019-12-24	Pyka	Y Combinator, DCVC, Bold Capital Partners, Greycroft, Prime Movers Lab
$12M2019-10-01	Molecular Assemblies	DCVC
$290M2019-09-19	Ginkgo Bioworks	Y Combinator, DCVC, Viking Global Investors, T. Rowe Price, General Atlantic, Baillie Gifford, Felicis
$151M2019-09-13	Element AI	DCVC
$160M2019-07-24	Freenome	Vasudev Bailey, S32, DCVC, Roche Venture Fund, T. Rowe Price, GV, BrightEdge, Section 32
$67M2019-06-25	Frontier Medicines	DCVC
$30M2019-06-12	Mythic	DCVC, Lux Capital, Shahin Farshchi, Matt Ocko
$120M2019-06-05	Sentinel One	DCVC
$—2019-02-11	PerimeterX	DCVC
$50M2019-01-17	Alation	Andreessen Horowitz, DCVC
$—2019	Alchemab Therapeutics	DCVC
$8M2018-12-11	GenEdit	Sequoia, Bowery Capital, DCVC, SK Group
$140M2018-11-15	Rocket Lab	Accel, K1W1, Future Fund, Greenspring Associates, DCVC, Khosla Ventures, Bessemer Venture Partners, David Cowan, Matt Ocko, Sven Strohband
$19M2018-09-26	Capella Space	DCVC, Matt Ocko
$30M2018-07-19	Embark Trucks	Sequoia, DCVC, Y Combinator, AME Cloud Ventures, SV Angel, Sequoia Capital, Matt Ocko
$65M2018-04-18	Tala	Founders Fund, Female Founders Fund, DCVC, Institutional Venture Partners, Ribbit Capital, Revolution Growth
$65M2018-04-01	Tala	Founders Fund, Female Founders Fund, Collaborative Fund, DCVC, Institutional Venture Partners, Ribbit Capital
$40M2018-03-20	Mythic	DCVC, Lux Capital, Shahin Farshchi, Matt Ocko
$45M2018-03-07	Atomwise	Khosla Ventures, Tencent Investment, DCVC, DFJ Growth, Dolby Family Ventures, Y Combinator, Baidu Ventures, Matt Ocko
$60M2017-10-03	Recursion Pharmaceuticals	DCVC, CRV, Felicis, Lux Capital
$18M2017-09-18	Cofactor Genomics	Y Combinator, WS Investment Company, DCVC, Menlo Ventures, iSelect Fund, Ascension Ventures, Matt Ocko
$15M2017-07-18	Embark	DCVC
$10M2017-07-11	Buoyant	Benchmark, DCVC
$102M2017-06-14	Element AI	DCVC
$64M2017-03-28	Rigetti	Andreessen Horowitz, DCVC, Lux Capital
$18M2017-03-14	Evolv Technologies	General Catalyst, DCVC, Lux Capital, Gates Ventures
$70M2017-01-25	Sentinel One	DCVC
$30M2017	Descartes Labs	DCVC
$11M2017	Aporeto	DCVC
$24M2017	Rigetti	Y Combinator, DCVC, Sutter Hill Ventures, Andreessen Horowitz, Streamlined Ventures, Lux Capital
$—2017	Halter	Founders Fund, DCVC
$65M2017	Freenome	Founders Fund, Innovation Endeavors, Andreessen Horowitz, DCVC, Polaris Partners
$9M2016-12-31	Mythic	DCVC, Lux Capital
$18M2016-11-01	Interana	DCVC
$4M2016-10-04	Paperspace	DCVC
$47M2016-08-22	LendUp	DCVC
$5M2016-06-09	Freenome	Founders Fund, Third Kind Venture Capital, DCVC
$10M2016-05-17	Agenovir	Lightspeed, DCVC, Celgene
$6M2016-03-24	Verdigris Technologies	DCVC
$160M2016	Freenome	S32, DCVC, Roche Venture Fund, T. Rowe Price, Andreessen Horowitz, GV, Section 32
$2M2015-10-13	Health Gorilla	DCVC
$—2015-10-01	Area 1 Security	DCVC, First Round
$9M2015-08-05	Amplitude, Inc.	DCVC, Eric Vishria
$42M2015-06-16	Zymergen	DCVC, Innovation Endeavors, Matt Ocko
$2M2015-06-16	SigOpt	DCVC
$30M2015-05-20	Metabiota	DCVC
$118M2015-04-13	Planet	Founders Fund, Innovation Endeavors, Industry Ventures, DCVC, Draper Fisher Jurvetson, First Round Capital, Felicis, First Round, Lux Capital
$118M2015-04-13	Planet Labs	Founders Fund, Innovation Endeavors, First Round Capital, Industry Ventures, DCVC, Draper Fisher Jurvetson
$9M2015-03-31	DroneDeploy	DCVC, Uncork Capital
$9M2015-03-18	Ginkgo Bioworks	DCVC, Felicis, Sundeep Peechu
$70M2015-01-20	Planet	DCVC, Chris Boshuizen, Shahin Farshchi, Zachary Bogue, Rob Hayes
$6M2014-11-06	Confluent	Benchmark, DCVC
$1M2014-07-14	Upside	Balderton Capital, DCVC
$10M2014-03-19	Blue River Technology	Khosla Ventures, Innovation Endeavors, DCVC, Matt Ocko
$1M2013-06-18	Ink File Picker	Y Combinator, DCVC, Streamlined Ventures, HighlandX, SV Angel, Workday Ventures
$4M2012-04-23	Locu	General Catalyst, DCVC, SV Angel, Lightbank, Quotidian Ventures, Matt Ocko, Lawrence Bohn
$1M2012	Scalus	DCVC
$46MUnknown date	Verdant Robotics	DCVC
$22MUnknown date	Valar Labs	DCVC
$16MUnknown date	Strateos	DCVC
$40MUnknown date	SF Compute	DCVC
$239MUnknown date	Recursion	DCVC
$22MUnknown date	Pendulum	DCVC
$54MUnknown date	Jupiter Intelligence	DCVC
$2MUnknown date	Iceberg Quantum	DCVC
$6MUnknown date	Iceberg Quantum	DCVC
$20MUnknown date	Fourth Power	DCVC
$30MUnknown date	Evonetix	DCVC
$3MUnknown date	Codesee	DCVC
$—Unknown date	Circularity Fuels	DCVC
$44MUnknown date	Cape Analytics	DCVC
$55MUnknown date	Brimstone	DCVC
$25MUnknown date	Axelar	DCVC
$6MUnknown date	Airthium	Y Combinator, DCVC, Polytechnique Ventures
$3MUnknown date	Sequence Bio	Y Combinator, DCVC, Pelorus Venture Capital, Killick Capital
$3MUnknown date	Cambio	Y Combinator, Goodwater Capital, DCVC, Integra Partners, Builders Vision, Leonis Investissement
$50MUnknown date	Karius	Khosla Ventures, Innovation Endeavors, Tencent Investment, DCVC
$60MUnknown date	Fulfil	Khosla Ventures, DCVC, Eclipse
$50MUnknown date	AIM Intelligent Machines	General Catalyst, Human Ventures, DCVC, Khosla Ventures, Ironspring Ventures
$65MUnknown date	Freenome	Founders Fund, Innovation Endeavors, DCVC, Andreessen Horowitz, Polaris Partners
$150MUnknown date	Impulse Space	Founders Fund, Airbus Ventures, Alumni Ventures, DCVC, 137 Ventures, Balerion Space Ventures
$150MUnknown date	Impulse Space	Founders Fund, Airbus Ventures, Alumni Ventures, DCVC, 137 Ventures, Balerion Space Ventures
$65MUnknown date	Tala	Founders Fund, Female Founders Fund, DCVC, Institutional Venture Partners, Ribbit Capital, Revolution Growth
$27MUnknown date	Gradle	Bain Capital, DCVC, StepStone Group, True Ventures, Harmony Partners, Triangle Peak Partners
$137M2026	Sidewinder Therapeutics	DCVC
$462M2025-12-10	Fervo	DCVC
$41M2025-04-09	Solu Therapeutics	DCVC
$132M2023-05-09	Ascend Gene & Cell Therapies	DCVC
$17M2023-02-20	Fortem Technologies	DCVC
$—2023	Sidewinder Therapeutics	DCVC
$—2022-11-29	Medical Informatics	DCVC
$4M2022-05-26	LivingCities	DCVC, ENIAC Ventures
$17M2022	Medical Informatics	DCVC
$30M2021-12-09	Petra	DCVC, 8VC, Chris Boshuizen
$60M2021	Alchemab	DCVC
$14M2020-09-30	Golden Recursion	Andreessen Horowitz, DCVC
$—2019	Alchemab	DCVC
$15M2018-03-14	Fortem Technologies	DCVC
$8M2018-02-06	Nyriad	DCVC
$7M2017-05-24	Merlon Intelligence	DCVC, Work-Bench
$8M2015-01-27	Nilas	DCVC
$10M2012-11-08	ElasticSearch	Benchmark, DCVC
$33MUnknown date	Novome	DCVC
$43MUnknown date	Novome	DCVC
$3MUnknown date	Nervana Systems	DCVC
$20MUnknown date	Nervana Systems	DCVC
$8MUnknown date	Molecular Stethoscope	DCVC
$48MUnknown date	Kanvas	DCVC
$1MUnknown date	Enzyme.com	DCVC
$10MUnknown date	Cardspring	DCVC
$55MUnknown date	Brimstone Energy	DCVC

Funds4

Team

Co-investing

Investments